Reduced-intensity ATRA plus arsenic with GO or low-dose anthracycline improves event-free survival in high-risk APL
New analysis shows reduced-intensity treatment works well for high-risk leukemia patients compared to standard intensive chemotherapy
This systematic review and meta-analysis of 1,323 patients with high-risk acute promyelocytic leukemia found that reduced-intensity inductio…
A large review of over 1,300 patients found that a gentler treatment plan worked just as well as harsher chemotherapy. This approach may hel…
Case report and review of TTMV::RARA-positive APL with spinal cord compression in a child
Doctors treated a boy with rare leukemia and spinal pressure using special drugs
This is a case report with a systematic review of 11 published cases of TTMV::RARA-positive acute promyelocytic leukemia (APL). The authors …
A nine-year-old boy had rare leukemia and spinal cord pressure. Doctors used specific drugs that helped clear the disease and fix his spine.
Review of ATRA and ATO induction therapy in acute promyelocytic leukemia with RNA sequencing insights
Why PCR Missed This Leukemia
This case report and literature review examines induction therapy using all-trans retinoic acid and arsenic trioxide in acute promyelocytic …
A standard blood test missed a dangerous leukemia because the disease had a unique genetic pattern that routine screening overlooked until a…
Phase II trial shows high remission and survival with frontline ATRA-ATO for newly diagnosed APL
Can a chemotherapy-free treatment beat a rare, aggressive leukemia?
A prospective multicenter phase II trial in 81 newly diagnosed APL patients in Japan found that frontline ATRA-ATO therapy achieved a 95.1% …
A chemotherapy-free treatment for acute promyelocytic leukemia achieved 95% remission and 95% survival three years later in a Japanese trial…
AI tool predicts acute leukemia subtypes with AUROC 0.94 for AML, 0.98 for promyelocytic, 0.84 for ALL in international cohort
Can a simple blood test help diagnose leukemia? An AI tool shows promise but still needs work
An AI tool was tested on a retrospective, international cohort of 6206 leukemia patients from 20 centers to predict acute leukemia subtypes …
An AI tool can spot leukemia from standard blood tests but must refuse to guess for most patients until doctors refine it to help more peopl…
Research across Leukemia
Related studies from across the Leukemia family.
TKI plus chemotherapy achieves deep molecular remission in Ph+ leukemia case with diagnostic framework
One patient's leukemia remission offers clues for rare diagnosis
This systematic review with a case report describes a patient with Philadelphia chromosome-positive leukemia who achieved complete remission…
A patient with a rare leukemia achieved deep remission for 35 months. The case highlights how to tell apart two similar-looking blood cancer…
Imatinib achieves complete cytogenetic response in a pediatric patient with suspected chronic myeloid leukemia
Imatinib works for CML in child with high platelets
This case report describes a pediatric patient with isolated thrombocytosis who achieved a complete cytogenetic response to imatinib after f…
A child with high platelets and no response to standard therapy was found to have CML and responded to imatinib.
Venetoclax plus intensive chemo yields 63.79% ORR in relapsed/refractory AML meta-analysis
Venetoclax combo shows promise for hard-to-treat leukemia
A meta-analysis of 235 patients with relapsed/refractory AML found that venetoclax combined with intensive chemotherapy achieved a pooled ov…
For patients with relapsed AML, venetoclax plus intensive chemo led to a 64% response rate in a new analysis.
GSTO1 inhibition induces apoptosis in AML cells while LMRS model stratifies patient risk
New lipid metabolism markers help predict outcomes for leukemia patients
This guideline synthesizes in vitro and observational data regarding lipid metabolism in acute myeloid leukemia (AML). The findings identify…
Researchers identified a new way to group and predict survival for patients with acute myeloid leukemia using lipid metabolism patterns.
Asparaginase therapy in acute lymphoblastic leukemia patients correlates with increased thromboembolism risk in specific subgroups
Adults with Leukemia Show Higher Risk of Blood Clots
This meta-analysis examined the incidence of thromboembolism among patients with acute lymphoblastic leukemia receiving asparaginase based c…
Patients with acute lymphoblastic leukemia treated with asparaginase face higher risks of blood clots, especially adults and those with spec…
Low-dose ATG plus PTCy shows no significant difference in acute GVHD compared to standard regimens
Trial Shows New Treatment Strategy for Leukemia Stem Cell Transplant
This randomized trial of 407 patients with AML or MDS undergoing haploidentical transplant found that low-dose ATG plus PTCy did not signifi…
A new combination of medications may help patients recover blood cells faster after a stem cell transplant for leukemia or blood disorders.
Venetoclax-based combinations show superior progression-free survival compared to chemoimmunotherapy in CLL without TP53 aberrations
Trial shows venetoclax combinations improve progression-free survival in CLL
This Phase 3 randomized controlled trial of 926 patients with CLL without TP53 aberrations found that venetoclax-based regimens (RV, GV, and…
New clinical trial results show that specific venetoclax combinations can keep chronic lymphocytic leukemia stable for longer than standard …
AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life
New combinations show promise for older adults with myeloid leukemia
This systematic review and meta-analysis of 47 studies evaluated treatments for older adults with AML ineligible for conventional chemothera…
Combining specific drugs like venetoclax with other treatments may improve survival and quality of life for older adults with acute myeloid …
7-day venetoclax with intensive chemotherapy achieves 90.3% composite complete remission in AML
Trial shows venetoclax combined with chemotherapy for AML
This clinical trial of 259 newly diagnosed patients with acute myeloid leukemia found a 90.3% composite complete remission rate using a 7-da…
A new clinical trial shows that a short 7-day course of venetoclax combined with chemotherapy can achieve high remission rates in AML patien…
Rate of drug concentration rise alters hemodynamic responses and mortality risk in coronary heart disease patients
New analysis shows how fast drug levels change affects patient safety outcomes
This narrative review and theoretical framework synthesizes evidence on rate-dependent pharmacology. It highlights divergent hemodynamic res…
This review explains that how quickly medicine levels rise in the body matters for safety. Fast changes can cause more harm than slow ones, …
Novel strategies aim to separate GVHD from GVL effects in allo-HCT for AML
Novel strategies aim to separate GVHD from GVL effects in leukemia patients
This narrative review explores novel therapeutic strategies to separate graft-versus-host disease (GVHD) from graft-versus-leukemia (GVL) ef…
A narrative review explores new ways to treat acute myeloid leukemia while managing side effects after stem cell transplants.
HMA-venetoclax yields 50% overall response rate in relapsed/refractory AML meta-analysis
Combination therapy shows response in relapsed leukemia
This systematic review and meta-analysis of 2289 adults with relapsed/refractory acute myeloid leukemia found that hypomethylating agents pl…
For adults with relapsed leukemia, combining two drugs led to a 50% response rate, offering a potential new option for a tough situation.
Questions about Acute Promyelocytic Leukemia
How effective is frontline ATRA-ATO therapy for newly diagnosed Acute Promyelocytic Leukemia?
Frontline ATRA-ATO therapy is highly effective for newly diagnosed APL, with complete remission rates over 94% and 3-year survival above 93% in clinical trials.
Full answer →Does the new AI test work well for distinguishing Acute Promyelocytic Leukemia from other types?
An AI tool shows very high accuracy for distinguishing Acute Promyelocytic Leukemia (APL) from other leukemias, with an AUROC of 0.98 in international tests, though it currently excludes many patients from predictions.
Full answer →What are the survival rates for Acute Promyelocytic Leukemia treated with ATRA and ATO?
ATRA plus ATO for APL achieves 3-year overall survival of 95% and 10-year survival of ≥80%, with complete remission rates over 95%.
Full answer →